background: burkitt lymphoma is a common subtype of non-hodgkin lymphoma in children. it has a rapid and aggressive clinical course with frequent involvement of bone marrow and central nervous system. systemic chemotherapy is the mainstay of the treatment for this malignancy in children. in this systematic review, we discuss autologous and allogeneic hematopoietic stem cell transplantation (hsc...

PURPOSE OF REVIEW Acute cerebral infarction causes irreversible locally restricted loss of the neuronal circuitry and supporting glial cells with consecutive functional deficits and disabilities. The currently available and effective therapy targets fast vessel recanalization accompanied by symptomatic measures. Research activities focusing on stem cells, which represent a promising source for ...

background: stem cell therapy is a new treatment option for different diseases. the aim of this systematic review is assessing the articles that focus on sct in iran and evaluate the amount of their success, failure and complication. methods: systematic search was conducted for finding english and persian papers (controlled trials and cohort studies with follow up) published before march 2015. ...

the increased risk of hemolytic reactions and erythrocyte recovery delay in abo incompatible hematopoietic stem cell transplantation (hsct) is well established. effects of abo incompatibility on transplantation outcomes is evaluated in this study. we prospectively followed 501 patients undergoing allogeneic stem cell transplantation according to abo compatibility groups of minor, major and bidi...

Background Donor Lymphocyte infusion (DLI) is a therapy for the patients with relapsed hematological malignancy after allogeneic hematopoetic stem cell transplantation. However, the development of Graft-Versus-Host Disease (GVHD) is a serious adverse event and the efficacy is limited when one needs to control the GVHD. To inhibit the development of GVHD with increased tumor-specificity of trans...

introduction: allogeneic hematopoietic cell transplantation (hsct) is the only therapeutic modality capable of correcting the hematologic manifestations of fanconi anemia (fa). the development  of well  tolerated,  immunosuppressive  conditioning  regimens  for fa patients  undergoing hsct has proven to be a rather challenging task for hematologists. methods: we analyzed the outcome of 30 fa pa...

conclusions in iran, hsct has been successfully adapted in routine clinical care. recently, new methods such as double cord blood and haploidentical transplantation have been used to treat many life-threatening diseases. results about 78.2% of the patients (2530 of 3237) remained alive between one to 211 months after stem cell transplantation. nearly, 21.8% (707) of our patients died after stem...